CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

Prospective Elimination of Distal Coronary Sinus to Left Atrial Connection for Atrial Fibrillation Ablation (PRECAF) Randomized Controlled Trial Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Trials Long-term Survival following Multivessel Revascularization in Patients with Diabetes (FREEDOM Follow-On Study) Spontaneous Coronary Artery Dissection: JACC State-of-the-Art Review Major trials in coronary intervention from 2018 How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD Left Ventricular Assist Device as a Bridge to Recovery for Patients With Advanced Heart Failure Stent fracture is associated with a higher mortality in patients with type-2 diabetes treated by implantation of a second-generation drug-eluting stent

Review Article2017 Jun 6;69(22):2759-2768.

JOURNAL:J Am Coll Cardiol. Article Link

LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation

Pothineni NVK, Karathanasis SK, Mehta JL et al. Keywords: LOX-1 blockers; coronary artery disease; endothelial cells; low-density lipoprotein; myocardial infarction; reactive oxygen species

ABSTRACT


Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), one of the scavenger receptors for oxidized low-density lipoprotein cholesterol (ox-LDL), plays a crucial role in the uptake of ox-LDL by cells in the arterial wall. Mounting evidence suggests a role for LOX-1 in various steps of the atherosclerotic process, from initiation to plaque destabilization. Studies of the genetic structure of LOX-1 have also uncovered various genetic polymorphisms that could modulate the risk of atherosclerotic cardiovascular events. As evidence supporting the vital role of LOX-1 in atherogenesis keeps accumulating, there is growing interest in LOX-1 as a potential therapeutic target. This review discusses the discovery and genetics of LOX-1; describes existing evidence supporting the role of LOX-1 in atherogenesis and its major complication, myocardial ischemia; and summarizes LOX-1 modulation by some naturally occurring compounds and efforts toward development of small molecules and biologics that could be of therapeutic use.